Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2

Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dua...

Full description

Bibliographic Details
Main Authors: Claudius Speer, Christian Morath, Maximilian Töllner, Mirabel Buylaert, Daniel Göth, Christian Nusshag, Florian Kälble, Matthias Schaier, Julia Grenz, Martin Kreysing, Paula Reichel, Asa Hidmark, Gerald Ponath, Paul Schnitzler, Martin Zeier, Caner Süsal, Katrin Klein, Louise Benning
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.721286/full
id doaj-e413afbaa85847fc89073dd1f5a18f3a
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Claudius Speer
Claudius Speer
Christian Morath
Maximilian Töllner
Mirabel Buylaert
Daniel Göth
Christian Nusshag
Florian Kälble
Matthias Schaier
Julia Grenz
Martin Kreysing
Paula Reichel
Asa Hidmark
Gerald Ponath
Paul Schnitzler
Martin Zeier
Caner Süsal
Katrin Klein
Louise Benning
spellingShingle Claudius Speer
Claudius Speer
Christian Morath
Maximilian Töllner
Mirabel Buylaert
Daniel Göth
Christian Nusshag
Florian Kälble
Matthias Schaier
Julia Grenz
Martin Kreysing
Paula Reichel
Asa Hidmark
Gerald Ponath
Paul Schnitzler
Martin Zeier
Caner Süsal
Katrin Klein
Louise Benning
Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
Frontiers in Medicine
SARS-CoV-2
COVID-19
hemodialysis
immune response
vaccination
author_facet Claudius Speer
Claudius Speer
Christian Morath
Maximilian Töllner
Mirabel Buylaert
Daniel Göth
Christian Nusshag
Florian Kälble
Matthias Schaier
Julia Grenz
Martin Kreysing
Paula Reichel
Asa Hidmark
Gerald Ponath
Paul Schnitzler
Martin Zeier
Caner Süsal
Katrin Klein
Louise Benning
author_sort Claudius Speer
title Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
title_short Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
title_full Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
title_fullStr Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
title_full_unstemmed Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2
title_sort humoral responses to single-dose bnt162b2 mrna vaccination in dialysis patients previously infected with sars-cov-2
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2021-08-01
description Seroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.
topic SARS-CoV-2
COVID-19
hemodialysis
immune response
vaccination
url https://www.frontiersin.org/articles/10.3389/fmed.2021.721286/full
work_keys_str_mv AT claudiusspeer humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT claudiusspeer humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT christianmorath humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT maximiliantollner humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT mirabelbuylaert humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT danielgoth humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT christiannusshag humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT floriankalble humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT matthiasschaier humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT juliagrenz humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT martinkreysing humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT paulareichel humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT asahidmark humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT geraldponath humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT paulschnitzler humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT martinzeier humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT canersusal humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT katrinklein humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
AT louisebenning humoralresponsestosingledosebnt162b2mrnavaccinationindialysispatientspreviouslyinfectedwithsarscov2
_version_ 1721205486623129600
spelling doaj-e413afbaa85847fc89073dd1f5a18f3a2021-08-17T05:07:51ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2021-08-01810.3389/fmed.2021.721286721286Humoral Responses to Single-Dose BNT162b2 mRNA Vaccination in Dialysis Patients Previously Infected With SARS-CoV-2Claudius Speer0Claudius Speer1Christian Morath2Maximilian Töllner3Mirabel Buylaert4Daniel Göth5Christian Nusshag6Florian Kälble7Matthias Schaier8Julia Grenz9Martin Kreysing10Paula Reichel11Asa Hidmark12Gerald Ponath13Paul Schnitzler14Martin Zeier15Caner Süsal16Katrin Klein17Louise Benning18Department of Nephrology, University of Heidelberg, Heidelberg, GermanyMolecular Medicine Partnership Unit Heidelberg, European Molecular Biology Laboratory (EMBL), Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Gastroenterology and Hepatology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyVirology, Department of Infectious Diseases, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanyDepartment of Nephrology, University of Heidelberg, Heidelberg, GermanySeroconversion rates following infection and vaccination are lower in dialysis patients compared to healthy controls. There is an urgent need for the characterization of humoral responses and success of a single-dose SARS-CoV-2 vaccination in previously infected dialysis patients. We performed a dual-center cohort study comparing three different groups: 25 unvaccinated hemodialysis patients after PCR-confirmed COVID-19 (Group 1), 43 hemodialysis patients after two-time BNT162b2 vaccination without prior SARS-CoV-2 infection (Group 2), and 13 single-dose vaccinated hemodialysis patients with prior SARS-CoV-2 infection (Group 3). Group 3 consists of seven patients from Group 1 and 6 additional patients with sera only available after single-dose vaccination. Anti-S1 IgG, neutralizing antibodies, and antibodies against various SARS-CoV-2 protein epitopes were measured 3 weeks after the first and 3 weeks after the second vaccination in patients without prior SARS-CoV-2 infection, 6 weeks after the onset of COVID-19 in unvaccinated patients, and 3 weeks after single-dose vaccination in patients with prior SARS-CoV-2 infection, respectively. Unvaccinated patients after COVID-19 showed a significantly higher neutralizing antibody capacity than two-time vaccinated patients without prior COVID-19 [median (IQR) percent inhibition 88.0 (71.5–95.5) vs. 50.7 (26.4–81.0); P = 0.018]. After one single vaccine dose, previously infected individuals generated 15- to 34-fold higher levels of anti-S1 IgG than age- and dialysis vintage-matched unvaccinated patients after infection or two-time vaccinated patients without prior SARS-CoV-2 infection with a median (IQR) index of 274 (151–791) compared to 18 (8–41) and 8 (1–21) (for both P < 0.001). With a median (IQR) percent inhibition of 97.6 (97.2–98.9), the neutralizing capacity of SARS-CoV-2 antibodies was significantly higher in single-dose vaccinated patients with prior SARS-CoV-2 infection compared to other groups (for both P < 0.01). Bead-based analysis showed high antibody reactivity against various SARS-CoV-2 spike protein epitopes after single-dose vaccination in previously infected patients. In conclusion, single-dose vaccination in previously infected dialysis patients induced a strong and broad antibody reactivity against various SARS-CoV-2 spike protein epitopes with high neutralizing capacity.https://www.frontiersin.org/articles/10.3389/fmed.2021.721286/fullSARS-CoV-2COVID-19hemodialysisimmune responsevaccination